ANI Pharmaceuticals (ANIP) Beats Stock Market Upswing: What Investors Need to Know
The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.17, reflecting a +1.37% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.22% gain on the day. At the same time, the Dow added 0.36%, and the tech-heavy Nasdaq gained 0.32%.
The drugmaker's stock has climbed by 3.71% in the past month, exceeding the Medical sector's gain of 2.3% and the S&P 500's gain of 1.61%.
Analysts and investors alike will be keeping a close eye on the performance of ANI Pharmaceuticals in its upcoming earnings disclosure. The company is expected to report EPS of $0.78, up 2.63% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $119.38 million, up 26.69% from the prior-year quarter.
Investors should also pay attention to any latest changes in analyst estimates for ANI Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. As of now, ANI Pharmaceuticals holds a Zacks Rank of #3 (Hold).
Digging into valuation, ANI Pharmaceuticals currently has a Forward P/E ratio of 13.65. Its industry sports an average Forward P/E of 22.43, so one might conclude that ANI Pharmaceuticals is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 96, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
